Month: February 2025

IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) — Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s fourth quarter and full year 2024 performance. The link to the webcast will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following link, which will provide you with dial-in details and...

– Full Year Revenues Increased 6.8% to a Record $890.2 Million Through Entirely Organic Growth, Including Geographical Expansion and Entry into Attractive Vinyl Market – – Full Year Single-Family Residential Revenue Grew to a Record $372.1 Million, Up 10.9% Year-Over-Year – – Full Year Net Income of $161.3 Million, or $3.43 Per Diluted Share; Full Year Adjusted Net Income1 of $171.6 Million, or $3.65 Per Diluted Share – – Full Year Adjusted EBITDA1 of $275.8 Million, Representing 31.0% of Revenues – – Full Year Gross Profit of $380.0 Million, Representing 42.7% of Revenues – – All-Time High Quarterly and Full Year Cash Flow from Operations of $61.1 Million and $170.5 Million Respectively, Representing 61.8% of Adjusted EBITDA1 for the Year – – All-Time Low Net...

Debt Restructuring with Maturity Extension and Covenant WaiverConcurrent $3.5 Million Capital Raise With Second Contingent Tranche of $4.5 MillionTransactions Significantly Increase Financial Flexibility and Liquidity RENO, Nev., Feb. 27, 2025 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (Nasdaq: DFLI), an industry leader in energy storage and battery technology, today announced the completion of an amendment of its existing debt facility and a concurrent $3.5 million registered direct offering and private placement of the Company’s Series A Convertible Preferred Stock (the “Preferred Stock”) with a single institutional investor, with a second contingent tranche of $4.5 million, subject to satisfaction of certain events as described below, which the Company believes significantly enhance...

Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an issued US method of treatment patent for potential treatment with simufilam of seizures related to rare neurodevelopmental disordersThe licensed patent is based on research led by Yale University and published in Science Translational Medicine showing that treatment with simufilam appeared to meaningfully reduce seizure frequency in an animal modelCassava will prioritize initial development efforts on tuberous sclerosis complex (TSC)-related seizuresAUSTIN, Texas, Feb. 27, 2025 (GLOBE NEWSWIRE) —  Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today...

PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March.TD Cowen 45th Annual Health Care Conference in Boston, MA, on Tuesday, March 4, 2025, at 9:50 a.m. ET Leerink Partners 2025 Global Healthcare Conference in Miami, FL, on Monday, March 10, 2025, at 10:00 a.m. ETA live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases....

Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share1 of $6.00-$6.25 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions. “We achieved significant revenue growth in 2024 driven by strong momentum across our major commercial programs,” said Todd Davis, CEO of Ligand. “Three of our portfolio products...